SCHEMBL4697286

SCHEMBL4697286

CC(C)(C)OC(=O)NCC(=O)Nc1ccc(CO)c(Cl)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKB Q96GD4 3/20 0.53
EGFR P00533 2/20 0.53
SUV39H2 Q9H5I1 3/20 0.53
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
RAF1 P04049 1/20 0.45
KDR P35968 1/20 0.45
MAP2K2 P36507 1/20 0.45
MAP2K1 Q02750 1/20 0.45
IDO1 P14902 2/20 0.44
HPGD P15428 2/20 0.43
GAA P10253 1/20 0.43
ALDH1A1 P00352 2/20 0.42
HDAC3 O15379 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC10 Q969S8 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
MET P08581 1/20 0.42
CYP3A4 P08684 1/20 0.42
CCNB2 O95067 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19932072 0.87 EGFR (0.57) AURKBEGFRSUV39H2MEN1KMT2A
SCHEMBL2290216 0.87 CA12 (0.45) SUV39H2MEN1KMT2AIDO1HPGD
SCHEMBL19931816 0.82 AURKB (0.52) AURKBEGFRSUV39H2MEN1KMT2A
SCHEMBL4751789 0.82 AURKB (0.51) AURKBEGFRSUV39H2MEN1KMT2A
SCHEMBL4697831 0.82 AURKB (0.57) AURKBEGFRSUV39H2MEN1KMT2A
SCHEMBL8693590 0.81 CA1 (0.54) AURKBEGFRSUV39H2MEN1KMT2A
SCHEMBL10862149 0.80 EGFR (0.52) AURKBEGFRSUV39H2MEN1KMT2A
SCHEMBL3218237 0.79 CA1 (0.48) AURKBEGFRSUV39H2MEN1KMT2A
SCHEMBL2472278 0.79 MAPK1 (0.57) AURKBEGFRSUV39H2MEN1KMT2A
SCHEMBL1828113 0.78 TSHR (0.56) MEN1KMT2AIDO1HPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1966222-A2 PYRAZOLOTHIAZOLE PROTEIN KINASE MODULATORS SGX Pharmaceuticals, Inc. (US) 2008-09-10 EP disclosed
US-20070173488-A1 Pyrazolothiazole Protein Kinase Modulators SGX PHARMACEUTICALS, INC. (US) 2007-07-26 US disclosed
US-20070173488-A1 Pyrazolothiazole Protein Kinase Modulators SGX PHARMACEUTICALS, INC. (US) 2007-07-26 US disclosed
US-20070173488-A1 Pyrazolothiazole Protein Kinase Modulators SGX PHARMACEUTICALS, INC. (US) 2007-07-26 US disclosed
WO-2007059341-A2 PYRAZOLOTHIAZOLE PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2007-05-24 WO disclosed
WO-2007059341-A2 PYRAZOLOTHIAZOLE PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2007-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173488-A1 Pyrazolothiazole Protein Kinase Modulators MAP4K2, MAP4K5, MAP4K3 AURKB 318/4885EGFR 603/4885SUV39H2 3037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.